KR20220016918A - 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법 - Google Patents

오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법 Download PDF

Info

Publication number
KR20220016918A
KR20220016918A KR1020217043400A KR20217043400A KR20220016918A KR 20220016918 A KR20220016918 A KR 20220016918A KR 1020217043400 A KR1020217043400 A KR 1020217043400A KR 20217043400 A KR20217043400 A KR 20217043400A KR 20220016918 A KR20220016918 A KR 20220016918A
Authority
KR
South Korea
Prior art keywords
group
alkyl
substituted
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217043400A
Other languages
English (en)
Korean (ko)
Inventor
벨루 메코넨
헤만트바이 파텔
Original Assignee
하거 바이오사이언시즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하거 바이오사이언시즈, 엘엘씨 filed Critical 하거 바이오사이언시즈, 엘엘씨
Publication of KR20220016918A publication Critical patent/KR20220016918A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217043400A 2019-06-04 2020-06-03 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법 Ceased KR20220016918A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856830P 2019-06-04 2019-06-04
US62/856,830 2019-06-04
PCT/US2020/035848 WO2020247445A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Publications (1)

Publication Number Publication Date
KR20220016918A true KR20220016918A (ko) 2022-02-10

Family

ID=73652477

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217043400A Ceased KR20220016918A (ko) 2019-06-04 2020-06-03 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법

Country Status (9)

Country Link
US (2) US12187737B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972588A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022534704A (cg-RX-API-DMAC7.html)
KR (1) KR20220016918A (cg-RX-API-DMAC7.html)
CN (1) CN114286675A (cg-RX-API-DMAC7.html)
AU (1) AU2020286381C1 (cg-RX-API-DMAC7.html)
CA (1) CA3140170A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112827QA (cg-RX-API-DMAC7.html)
WO (1) WO2020247445A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101004A1 (ko) * 2023-11-08 2025-05-15 한양대학교 에리카산학협력단 6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
WO2025188753A1 (en) * 2024-03-05 2025-09-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237988A (ja) 1988-11-18 1990-09-20 Nissan Chem Ind Ltd イソオキサゾロピリジン系メバロノラクトン類
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
JP3810097B2 (ja) 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−2−イルカルボニル複素環式化合物誘導体
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
SK7582001A3 (en) 1998-12-18 2002-03-05 Schering Corp Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1289955B1 (en) 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
BR0209334A (pt) 2001-05-05 2004-06-15 Smithkline Beecham Plc Aminas n-aroil cìclicas
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2004026866A1 (en) * 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
SI1836211T1 (sl) 2004-12-21 2010-04-30 Pfizer Prod Inc Makrolidi
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US20090118200A1 (en) 2005-05-23 2009-05-07 Bergman Jeffrey M Proline bis-amide orexin receptor antagonists
UA100974C2 (ru) * 2006-12-01 2013-02-25 Мерк Шарп Энд Доме Корп. Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HRP20120240T1 (hr) 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
FR2925907B1 (fr) 2008-01-02 2010-10-15 Sanofi Aventis DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CN101918361B (zh) 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
AU2009307920A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506374A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
WO2010141275A1 (en) 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
EP2630138B1 (en) * 2010-10-21 2015-06-03 Bayer Intellectual Property GmbH 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
ES2541531T3 (es) * 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
EP2730573A4 (en) 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
US9242995B2 (en) 2011-10-25 2016-01-26 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101004A1 (ko) * 2023-11-08 2025-05-15 한양대학교 에리카산학협력단 6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물

Also Published As

Publication number Publication date
US12187738B2 (en) 2025-01-07
US12187737B2 (en) 2025-01-07
CN114286675A (zh) 2022-04-05
CA3140170A1 (en) 2020-12-10
WO2020247445A1 (en) 2020-12-10
EP3972588A4 (en) 2023-05-31
JP2022534704A (ja) 2022-08-03
EP3972588A1 (en) 2022-03-30
US20240409554A1 (en) 2024-12-12
AU2020286381B2 (en) 2025-04-03
AU2020286381A1 (en) 2022-01-20
SG11202112827QA (en) 2021-12-30
AU2020286381C1 (en) 2025-07-10
US20220259224A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
US12187738B2 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
US12275744B2 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
AU2013327505B2 (en) Anti-fibrotic pyridinones
AU2021286738A1 (en) Phthalazinone compound, and preparation method therefor and medical use thereof
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
TW202039471A (zh) Apol1抑制劑及其使用方法
TW202333674A (zh) 作為glp-1受體調節劑之某些2,5-二氮雜雙環〔4.2.0〕辛烷
TW202333721A (zh) 作為GLP—1受體調節劑之某些八氫呋喃并[3,4—b]吡𠯤
US20170008883A1 (en) Substituted thiazole or oxazole p2x7 receptor antagonists
JP2024510935A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
EP4119555A1 (en) Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
KR20200040841A (ko) 벤젠 축합 헤테로환 유도체 및 이를 포함하는 약학 조성물
KR20240091018A (ko) Rxfp1 효능제
US20250268903A1 (en) Rxfp1 agonists
EP4662201A1 (en) Biaryl amide-containing agonists of orexin receptor type 2
WO2024044351A2 (en) Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders
WO2025188753A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601